A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

    Study Chair
    Dr. Lorenzo Gianni, Rimini, Italy

    Lead Trial Coordinator
    Holly Shaw

    Trial Coordinators
    Poonam Jani

    Trial Monitor
    Giuseppe Achille, Daniela Celotto, Carmen Comune, Lionel Nobs

    IBCSG Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


    Date of Activation
    July 25, 2014

    Targeted Accrual
    1320

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login